Lloyd R. Whitfield
- Pharmacology top 2%
- Pharmacogenetics and Drug Metabolism 6
- Antibiotics Pharmacokinetics and Efficacy 6
- Oncology top 10%
- Internal Medicine top 10%
- Surgery top 10%
- Lipoproteins and Cardiovascular Health 9
- Ophthalmology top 5%
-
- Cancer therapeutics and mechanisms 7
-
- Computational Drug Discovery Methods 5
-
- Pharmacological Effects and Toxicity Studies 5
-
- HIV/AIDS drug development and treatment 4
-
- Analytical Methods in Pharmaceuticals 4
- Co-authors
- Barbra H. StewartXiaochun WuGerhard LevyAllen J. SedmanDonald M. GibsonR. H. SternDonald D. CillaRebecca A. Boyd
- Journals
- Journal of Clinical Oncology (1 paper)Annals of Surgery (2 papers)Annals of the New York Academy of Sciences (1 paper)
- Partner nations
- United StatesCanadaChina
In The Last Decade
Lloyd R. Whitfield
46 papers receiving 1.1k citations
Peers
Comparison fields: 5 of 94
- Pharmacology 216
- Oncology 325
- Internal Medicine 42
- Surgery 359
- Ophthalmology 73
Countries citing papers authored by Lloyd R. Whitfield
This map shows the geographic impact of Lloyd R. Whitfield's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lloyd R. Whitfield with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lloyd R. Whitfield more than expected).
Fields of papers citing papers by Lloyd R. Whitfield
This network shows the impact of papers produced by Lloyd R. Whitfield. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lloyd R. Whitfield. The network helps show where Lloyd R. Whitfield may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Lloyd R. Whitfield, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2010 | 42 | |
| 2 | Population Pharmacokinetics/Pharmacodynamics (PK/PD) of Pegaptanib Sodium (Macugen®) in Patients with Age–Related Macular Degeneration (AMD) | 2006 | 4 |
| 3 | 2005 | 21 | |
| 4 | 2002 | 9 | |
| 5 | 2000 | 153 | |
| 6 | 2000 | 139 | |
| 7 | 2000 | 26 | |
| 8 | 1998 | 15 | |
| 9 | 1998 | 18 | |
| 10 | 1996 | 72 | |
| 11 | 1995 | 4 | |
| 12 | 1993 | 1 | |
| 13 | 1992 | 4 | |
| 14 | Phase I and pharmacokinetic study of the novel platinum analogue CI-973 on a 5-daily dose schedule. | 1992 | 13 |
| 15 | 1991 | 1 | |
| 16 | 1990 | 4 | |
| 17 | Development of a radioimmunoassay for the anthrapyrazole chemotherapy agent CI-937 and the pharmacokinetics of CI-937 in rats. | 1989 | 8 |
| 18 | 1985 | 7 | |
| 19 | 1981 | 21 | |
| 20 | 1976 | 8 |
About Lloyd R. Whitfield
Lloyd R. Whitfield is a scholar working on Internal Medicine, Pharmacology and Analytical Chemistry, having authored 48 papers that have together received 1.2k indexed citations. Recurring topics across this work include Lipoproteins and Cardiovascular Health (9 papers), Cancer therapeutics and mechanisms (7 papers), Pharmacogenetics and Drug Metabolism (6 papers), Antibiotics Pharmacokinetics and Efficacy (6 papers), Computational Drug Discovery Methods (5 papers), Pharmacological Effects and Toxicity Studies (5 papers), HIV/AIDS drug development and treatment (4 papers) and Analytical Methods in Pharmaceuticals (4 papers). The work is most often cited by research in Pharmacology (216 citations), Oncology (325 citations) and Internal Medicine (42 citations). Lloyd R. Whitfield has collaborated with scholars based in United States, Canada and China. Frequent co-authors include Barbra H. Stewart, Xiaochun Wu, Gerhard Levy, Allen J. Sedman, Donald M. Gibson, R. H. Stern, Donald D. Cilla, Rebecca A. Boyd, Eric L. Reyner and Edward J. Randinitis. Their work appears in journals such as Journal of Clinical Oncology, Annals of Surgery and Annals of the New York Academy of Sciences.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.